Japan’s FY2024 pharmaceutical sales revealed a sharp divergence among immune checkpoint inhibitors as MSD’s Keytruda (pembrolizumab) surged toward the 200-billion-yen…
HOME > ACADEMIA
ACADEMIA
- Alzheimer’s-Related Guidelines Being Revised to Accommodate Kisunla, Rexulti
November 6, 2024
- Japan Crafting Registry of All Hemophilia Patients, Company Use Eyed Too
November 5, 2024
- Pricing Partially to Blame for Diabetes Drug Shortage: Society Chair
November 5, 2024
- 50% of Quit-Smoking Clinics Closed or Suspended, Will Champix Re-Supply Bring Them Back Online?
October 30, 2024
- Local Anesthetic Supply Won’t Recover Soon Despite New Site Approval: Specialist
October 28, 2024
- Academic Societies Urge COVID-19 Vaccinations, Deny Kostaive “Shedding”
October 22, 2024
- Non-HCPs Have Higher Expectations of Alzheimer’s Drugs than Specialists: Poll
October 7, 2024
- Pharmacies, Hospitals Scrambling to Address New LLP Coverage Rule, Concerns Swirl Around Misuse
October 1, 2024
- KOL Calls for Public Support for Truvada’s PrEP Use against HIV
September 26, 2024
- Early Use of High-Dose Mecobalamin Extends Survival in ALS: IIT Data
September 20, 2024
- NCC, Eisai Confirm Tumor Shrinkage with E7820 Using J-PDX Models
September 17, 2024
- Japan Study Finds No Evidence of Increased Cancer Risk for Sitagliptin
September 3, 2024
- A Time for Patience - 5: Focus Turning to Early and Preclinical ALS Treatment, TDP-43 as New Target
August 28, 2024
- As Kisunla Approval Nears, Japanese Alzheimer’s KOL Hails Increase in Options
August 9, 2024
- Japan’s Antibiotic Use Up 22.3% in 2023 after COVID Restrictions Lifted
August 7, 2024
- NCC Out-Licenses UPenn-Partnered Cell Therapy to Spinout Company
July 12, 2024
- 8.5% of Long-COVID Patients Still Seriously Affected after 6 Months: Survey
July 4, 2024
- Academic Society Frets Availability of 1st-Gen Oral Cephems amid Choseido Halt
June 24, 2024
- MHLW-Funded Study Group Designing New Care Delivery Model for Alzheimer’s
June 14, 2024
- Leukemia Drug Slows ALS Progression in Japan Clinical Trial
June 13, 2024
ページ
I recently attended a fantastic conference hosted by Prospection Japan, and one speaker, Dr. Joe Ledsam, really blew me away with his insights. He shared some truly fascinating developments about how AI is set to revolutionize healthcare, from how doctors…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…